Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17).

被引：0

作者：

Lee, Kyoungmin

Lee, Kyung-Hun

Kim, Dong-Wan

Yoon, Jeesun

Choi, Wonyoung

Lee, Youngjoo

Choi, Yoon Ji

Lee, Soohyeon

Kim, Ju Won

Ryu, Hyewon

Koo, Dong-Hoe

Lee, Yun-Gyoo

Jeung, Hei-Cheul

Lee, Min-Young

Lee, Namsu

Kang, Myoung Joo

Lee, Ji Eun

Hong, Sook Hee

Kang, Eun Joo

Park, Inhae

机构：

[1] Korea Univ, Div Hematol Oncol, Dept Internal Med, Guro Hosp,Coll Med, Seoul, South Korea

[2] Seoul Natl Univ, Dept Internal Med, Seoul Natl Univ Hosp, Coll Med,Canc Res Inst, Seoul, South Korea

[3] Seoul Natl Univ, Dept Internal Med, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea

[4] Seoul Natl Univ, Dept Internal Med, Seoul Natl Univ Hosp, Seoul, South Korea

[5] Seoul Natl Univ, Canc Res Inst, Seoul, South Korea

[6] Natl Canc Ctr, Div Hematol & Oncol, Dept Internal Med, Goyang, South Korea

[7] Natl Canc Ctr, Div Hematol & Oncol, Dept Internal Med, Goyang Si, South Korea

[8] Korea Univ, Div Hematol Oncol, Dept Internal Med, Anam Hosp,Coll Med, Seoul, South Korea

[9] Korea Univ, Anam Hosp, Coll Med, Seoul, South Korea

[10] Korea Univ, Anam Hosp, Seoul, South Korea

[11] Chungnam Natl Univ Hosp, Div Hematol & Oncol, Dept Internal Med, Coll Med, Daejeon, South Korea

[12] Sungkyunkwan Univ, Div Hematol Oncol, Dept Internal Med, Kangbuk Samsung Hosp,Sch Med, Seoul, South Korea

[13] Yonsei Univ, Dept Med Oncol, Gangnam Severance Hosp, Coll Med, Seoul, South Korea

[14] Soonchunhyang Univ, Div Hematol & Oncol, Dept Internal Med, Seoul Hosp, Seoul, South Korea

[15] Inje Univ, Haeundae Paik Hosp, Div Hematol Oncol, Dept Internal Med, Busan, South Korea

[16] Catholic Univ Korea, Div Med Oncol, Dept Internal Med, Seoul St Marys Hosp,Coll Med, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3134

引用

页数：1

共 50 条

[31] A phase I study of the tolerability, safety, pharmacokinetics and preliminary antitumor effects of KBP-5209, a novel pan-HER inhibitor, in patients with advanced solid tumors.
Piha-Paul, Sarina Anne
Sharma, Sunil
Shih, Chengkon
O'Neil, Bert H.
Zhou, Qinghong
Ding, Yuli
Ou, Na
Yu, Tingting
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[32] Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
Sun, Ying
Chen, Beibei
Li, Jisheng
Peng, Ling
Li, Shuguang
Yu, Xuejun
Li, Li
CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 7165 - 7174
[33] Open-label, dose-escalation phase 1a study of SPH5030, a tyrosine kinase inhibitor (TKI) targeting HER2, in patients with HER2 positive advanced solid tumors
Wang, Jiayu
Wang, Wenna
Tong, Zhongsheng
Shi, Yehui
Shi, Yanxia
Zheng, Qiufan
Yu, Shunjiang
Cao, Yuanyuan
Xie, Ning
Fan, Jianru
Xu, Binghe
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[34] A phase II study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification
Zhou, C.
Li, X.
Yu, Q.
Ning, R.
Sun, M.
Wang, Q.
Liu, A.
Tang, H.
Tian, X.
Zhou, Y.
Wei, Z.
ANNALS OF ONCOLOGY, 2024, 35 : S825 - S825
[35] Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors
Zhou, Caicun
Yang, Bo
Deng, Ting
Wang, Biyun
Zhang, Jian
Sun, Yuping
Wang, Linlin
Yang, Hongwei
Wang, Jingfen
Li, Wei
Song, Qi
Yang, Yuchong
CANCER RESEARCH, 2024, 84 (07)
[36] Phase Ia/Ib trial of the HER2 tyrosine kinase inhibitor zongertinib (BI 1810631) in patients with HER2-driven solid tumors: Focus on Asian patients
Yoh, K.
Opdam, F.
Barve, M.
Tu, H.
Wu, Y-L.
Berz, D.
Schroeter, L.
Sadrolhefazi, B.
Serra, J.
Heymach, J.
Yamamoto, N.
ANNALS OF ONCOLOGY, 2024, 35 : S1637 - S1638
[37] A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumours
Tan, A. C.
Seet, A. O. L.
Choo, S. P.
Tai, D. W. M.
Lam, Y. C. J.
Teng, W. T.
Lim, C.
Lim, K. H.
Ng, M. C. H.
ANNALS OF ONCOLOGY, 2019, 30
[38] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours.
Agus, D. B.
Terlizzi, E.
Stopfer, P.
Amelsberg, A.
Gordon, M. S.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 97S - 97S
[39] Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data.
Heymach, John
Opdam, Frans
Barve, Minal A.
Tu, Hai-Yan
Wu, Yi-Long
Berz, David
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yoh, Kiyotaka
Yamamoto, Noboru
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[40] Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
Heymach, John
Opdam, Frans
Barve, Minal
Tu, Hai-Yan
Wu, Yi-Long
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yoh, Kiyotaka
Yamamoto, Noboru
CANCER RESEARCH, 2023, 83 (08)

← 1 2 3 4 5 →